Literature DB >> 4040887

Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device.

G Berglund, U De Faire, J Castenfors, G Andersson, M Hartford, H Liedholm, S Ljungman, T Thulin, J Wikstrand.   

Abstract

To test the usefulness of noninvasive ambulatory 24-hour blood pressure recording, the Del Mar Avionics system was used in a double-blind clinical trial in which 31 hypertensive patients were randomly allocated to receive placebo or pafenolol (25 mg or 50 mg), a novel, long-acting, highly selective beta-blocker, once daily. The results of 24-hour blood pressure and heart rate recording after 4 weeks of treatment were compared with a previous 24-hour recording performed after a 4-week placebo run-in period using the 3-hour mean of recordings performed every 7.5 minutes both day and night. Furthermore, 24-hour means were analyzed in each patient before and after 4 weeks. The system was easy to use and, judging from two placebo periods in the same patients, the reproducibility was good. The 24-hour blood pressure and heart rate recordings showed a clear dose-response relationship for pafenolol that could not be detected by ordinary casual readings. A daily dose of 25 mg of pafenolol significantly reduced blood pressure during the 9 hours after tablet intake (p less than 0.01), while 50 mg per day of pafenolol resulted in a significant reduction throughout the 24-hour period (p less than 0.01). The same pattern was seen for heart rate, which indicates a greater degree of beta-blockade during treatment with the higher dose. These results indicate that the tested noninvasive equipment is a useful tool for monitoring ambulatory 24-hour blood pressure. It gives important information impossible to obtain from single casual readings. This noninvasive method should be further evaluated to define its place in clinical work and as a research tool.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040887     DOI: 10.1161/01.hyp.7.5.688

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.

Authors:  C G Regårdh; P Lundborg; M Gabrielsson; A Heggelund; K Kylberg-Hanssen
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

2.  Sustained release verapamil in renal hypertension.

Authors:  H Eiskjaer; E B Pedersen; L M Rasmussen; B Jespersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Comparison of once and twice daily administration of captopril plus hydrochlorothiazide on 24 h blood pressure levels.

Authors:  L Poggi; B Vaisse; F Bernard; J Drivet-Perrin; R Sambuc
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

4.  Once daily nisoldipine in hypertension: cuff and ambulatory intra-arterial blood pressure.

Authors:  G Brigden; M Heber; M Caruana; A Lahiri; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

Authors:  L Corea; M Bentivoglio; S Berioli; C Bianchini; K Savino; M Sardina
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

6.  Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours.

Authors:  Gianfranco Parati; Stefano Omboni; Paolo Palatini; Damiano Rizzoni; Grzegorz Bilo; Mariaconsuelo Valentini; Enrico Agabiti Rosei; Giuseppe Mancia
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

7.  Antihypertensive efficacy of twice daily controlled release diltiazem using 24 hour intra-arterial blood pressure monitoring.

Authors:  B S Sridhara; P Thomas; A Lahiri; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.

Authors:  Gavin W K Wong; Heidi N Boyda; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2016-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.